Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021
November 04, 2021 17:34 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Participation in November Conferences
November 04, 2021 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Release Third Quarter Financial Results on Thursday, November 11, 2021
November 01, 2021 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium
October 07, 2021 07:51 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress
October 05, 2021 16:22 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals to Present at Two Investor Conferences in September
September 01, 2021 16:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...
Eledon Pharmaceuticals Reports Second Quarter 2021 Operating and Financial Results
August 12, 2021 16:01 ET
|
Eledon Pharmaceuticals, Inc.
Received approval from Health Canada to initiate a clinical trial of AT-1501 in kidney transplantation; company expects to initiate trial in Q4 with initial data in late 2022 Reached agreement with...
Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021
August 02, 2021 08:05 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines...
Eledon Pharmaceuticals Receives Health Canada Approval to Commence Human Trials to Evaluate AT-1501 in Kidney Transplantation
July 26, 2021 08:00 ET
|
Eledon Pharmaceuticals, Inc.
Interim data expected in late 2022 in a multicenter, open label study to replace tacrolimus with AT-1501 IRVINE, Calif., July 26, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”)...
Eledon Pharmaceuticals Appoints Jan Hillson, M.D., to its Board of Directors
July 02, 2021 08:00 ET
|
Eledon Pharmaceuticals, Inc.
IRVINE, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing targeted medicines for...